• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
170132 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  9 g) [; n7 o7 R
& F# T) d; _+ [
; g/ H4 |7 e' d  t
Sub-category:! H! l2 L2 f1 g: Z
Molecular Targets # V! u" W1 f8 k! x. ~0 r# Z

+ k/ j  V: d" R7 A0 o8 I: |3 g8 b3 E7 A7 x$ {1 M2 x
Category:  R* T: H# P, n: _. d6 a9 B% J# s
Tumor Biology
" e/ v5 m% r8 A$ _1 i% C' a
% n; z4 F0 {- ]) H; \$ u3 g7 ~; Z# X* N7 g# r$ e' Z! n4 }: n
Meeting:% o$ C6 \7 E: {  u" f
2011 ASCO Annual Meeting / [% ?% U4 f! j$ z$ K; p

2 g0 \+ J, s9 [8 _& j& h0 l1 y8 E* o  f: y) Q5 m
Session Type and Session Title:
- ~) ?8 N/ G2 E; l% _/ iPoster Discussion Session, Tumor Biology 0 k9 Q" \' w' G) ?# O! K* ^

7 H& r- K! o! F# c- w* B9 d. J
3 ^% M  W9 s8 a" LAbstract No:3 ~) K9 }0 r* Q& P8 g
10517
0 G* F5 g7 W( a, ?8 t! J6 v6 ?& A% [2 R! M4 ]! K% `- c
8 k) r0 E3 S4 M( J0 w& B; m
Citation:+ e4 t2 c9 h6 h6 M0 m& ]
J Clin Oncol 29: 2011 (suppl; abstr 10517)
5 ^  D6 C# D1 p* n6 v  e+ H3 t, Q+ m$ n! `: G! x
1 O3 A, m2 T2 c. \# ?
Author(s):
9 v% Z+ w2 c0 a6 ~) c- fJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
2 _5 J% d& M9 q( i# O1 M. k% B; V. f
  e; z& o" r. H( k

" f0 G+ ~. g, ]7 T7 B+ ]" ^Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
& p  Y4 \2 P) A3 N! {6 [0 J$ Q$ n# a) }- X; S6 ~
Abstract Disclosures1 Q$ h. ^4 q# g0 M
/ j9 S3 ]1 D# |" B
Abstract:) }" f8 H6 H. Q& f- V  `

( W2 p! u" ~3 U3 ^5 p: b% x! r" F: j4 z( G3 b& \
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.# x( \2 e5 C% \4 C& u" Q- V
# W8 x; |( a' Z  [' W

- A. ~) D, |& i& i7 f, Y" E8 s
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
7 q% `) H8 o" D4 I' B# q没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
, s0 q: b8 R3 E1 X. s
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
$ H! D, B3 ^0 Q% r% M9 B- r, F易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。; b, b. Z& A5 e4 O1 U/ X8 i/ u
ALK一个指标医院要900多 ...
& g. m; [/ `/ Y- u9 ]8 M
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?, f7 h, U6 @* k$ V( X" d

9 z  m1 X1 M8 V0 w) v现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表